Advanced in Neurosarcoidosis

Dr. Amit Agarwal

Internal Medicine
Das Medical Associates
1 Sears Drive, Suite 402, 
Paramus, NJ 
Advanced in Neurosarcoidosis
Das Medical Associates
1 Sears Drive, Suite 402, 
Paramus, NJ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Amit Agarwal is a primary care provider, practicing in Internal Medicine in Paramus, New Jersey. Dr. Agarwal is rated as an Advanced provider by MediFind in the treatment of Neurosarcoidosis. His top areas of expertise are Tracheobronchomalacia, Acute Kidney Failure, Lung Cancer, Parathyroidectomy, and Thyroidectomy.

His clinical research consists of co-authoring 699 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles in the study of Neurosarcoidosis.

Graduate Institution
Ross University School Of Medicine-Dominica
Residency
Trinitas Regional Medical Center
Specialties
Internal Medicine
Licenses
Internal Medicine in MN
Board Certifications
American Board Of Internal Medicine
Hospital Affiliations
Hackensack University Medical Center
Valley Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

Das Medical Associates
1 Sears Drive, Suite 402, Paramus, NJ 7652.

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Randomized, Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib, and Dexamethasone (RVD) to High-Dose Treatment With Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients Up to 65 Years of Age
A Randomized, Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib, and Dexamethasone (RVD) to High-Dose Treatment With Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients Up to 65 Years of Age
Enrollment Status: Active_not_recruiting
Publish Date: January 22, 2026
Intervention Type: Drug, Procedure
Study Drugs: Lenalidomide, Bortezomib, Dexamethasone
Study Phase: Phase 3
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Phase 1a/1b Multicenter, Single-Arm, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Preliminary Activity of Oral ACY-241 Alone and in Combination With Pomalidomide and Low-Dose Dexamethasone in Patients With Relapsed or Relapsed-and-Refractory Multiple Myeloma
A Phase 1a/1b Multicenter, Single-Arm, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Preliminary Activity of Oral ACY-241 Alone and in Combination With Pomalidomide and Low-Dose Dexamethasone in Patients With Relapsed or Relapsed-and-Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: July 09, 2024
Intervention Type: Drug
Study Drugs: ACY-241, Pomalidomide, Dexamethasone
Study Phase: Phase 1
A Randomized, Multicenter, Multinational, Double-Blind Study to Assess the Efficacy and Safety of MB02 (Bevacizumab Biosimilar Drug) Versus Avastin® in Combination With Carboplatin and Paclitaxel for the Treatment of Subjects With Stage IIIB/IV Non-squamous Non-Small Cell Lung Cancer (NSCLC)
A Randomized, Multicenter, Multinational, Double-Blind Study to Assess the Efficacy and Safety of MB02 (Bevacizumab Biosimilar Drug) Versus Avastin® in Combination With Carboplatin and Paclitaxel for the Treatment of Subjects With Stage IIIB/IV Non-squamous Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Completed
Publish Date: April 26, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 3 Less Clinical Trials

3 Total Publications

Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM.
Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM.
Journal: Blood
Published: June 06, 2017
Similar Doctors
Distinguished in Neurosarcoidosis
Dr. Joseph Grizzanti
Internal Medicine
Distinguished in Neurosarcoidosis
Dr. Joseph Grizzanti
Internal Medicine

Sovereign Medical Group LLC

85 Harristown Rd Ste 101, 
Glen Rock, NJ 
 (3.2 miles away)
973-790-4111
Languages Spoken:
English
See accepted insurances

Joseph Grizzanti is an Internal Medicine provider in Glen Rock, New Jersey. Dr. Grizzanti is rated as a Distinguished provider by MediFind in the treatment of Neurosarcoidosis. His top areas of expertise are Eosinophilic Asthma, Asthma, Sarcoidosis, and Asthma in Children.

Sergio Bures
Advanced in Neurosarcoidosis
Dr. Sergio Bures
Internal Medicine | Pulmonary Medicine
Advanced in Neurosarcoidosis
Dr. Sergio Bures
Internal Medicine | Pulmonary Medicine
111 Bedford Road, 
Katonah, NY 
 (28.8 miles away)
914-232-3135
Languages Spoken:
English, Spanish
See accepted insurances
Offers Telehealth

Sergio Bures is an Internal Medicine specialist and a Pulmonary Medicine provider in Katonah, New York. Dr. Bures is rated as a Distinguished provider by MediFind in the treatment of Neurosarcoidosis. His top areas of expertise are Lung Metastases, Chronic Obstructive Pulmonary Disease (COPD), Lung Nodules, and Asthma.

Advanced in Neurosarcoidosis
Dr. David Steiger
Internal Medicine
Advanced in Neurosarcoidosis
Dr. David Steiger
Internal Medicine

Ear Nose And Throat (Ent) Mount Sinai Union Square

10 Union Sq E Ste 2A, 
New York, NY 
 (16.0 miles away)
212-420-2377
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Steiger is an Internal Medicine provider in New York, New York. Dr. Steiger is rated as an Advanced provider by MediFind in the treatment of Neurosarcoidosis. His top areas of expertise are Emphysema, Bullae, Acute Interstitial Pneumonia, and Interstitial Lung Disease.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Agarwal's expertise for a condition
ConditionClose
    View All 25 Advanced Conditions
    View All 238 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile